Artiva Biotherapeutics, Inc. 4

Artiva Biotherapeutics CMO Subhashis Banerjee received 30,000 RSUs and options for 85,000 shares of common stock at $10.79 per share as equity compensation.

On September 9, 2026, Chief Medical Officer Subhashis Banerjee of Artiva Biotherapeutics, Inc. received two equity-based compensation grants: 30,000 shares of common stock in the form of restricted stock units under the issuer’s 2024 Equity Incentive Plan, and an employee stock option to purchase 85,000 shares of common stock at an exercise price of $10.79 per share, with the option scheduled to vest in 1/48th monthly installments beginning September 8, 2026, over four years. Following these awards, Banerjee beneficially owned 170,947 shares of common stock, with the RSU and option grants representing standard executive compensation rather than open-market purchases or sales. Using the option exercise price as a proxy for the stock price, the RSU grant is valued at approximately $323,700 and the option grant represents an option value on underlying shares of about $917,150, and his post-transaction holdings are worth roughly $1.84 million on the same price basis.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-389510

Alert Tier

5